The Arabic allele: a single base pair substitution activates a 10-base downstream cryptic splice acceptor site in exon 12 of LDLR and severely decreases LDLR expression in two unrelated Arab families with familial hypercholesterolemia
When one member of a family has early heart disease, screen the entire family for familial hypercholesterolemia
Methods: Fifty patients with hypercholesterolemia
and twenty controls were selected after getting informed consent regarding the investigation of carotid-intima media thickness by B-mode ultrasound.
The molecular analysis of familial hypercholesterolemia
(FH), an autosomal dominant disease caused by a multitude of LDL receptor (LDLR) gene mutations, is complicated by mutational heterogeneity of the disease in the majority of population studied to date [10,11].
in the danish general population: prevalence, coronary artery disease, and cholesterol-lowering medication.
04 respectively) and for developing hypercholesterolemia
(OR - 2.
Biopharmaceutical company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) reported on Thursday the receipt of the US Food and Drug Administration (FDA) Breakthrough Therapy designation status for evinacumab for the treatment of hypercholesterolemia
in patients with Homozygous Familial Hypercholesterolemia
, atherosclerosis, CD40 ligand cok LDL-kolesterol, trigliserit, 8-OHdG, F1+2 arasinda anlamli korelasyon kurulamamistir (p>0,005).
The other was a rat model, and the animals were fed a high-cholesterol diet, causing diet-induced hypercholesterolemia
The findings presented at ESC 2016, alongside the six new clinical trials that have begun in the last year, will better define the benefit of Repatha for the many patients who continue to struggle with hypercholesterolemia
The report provides comprehensive information on the therapeutics under development for Heterozygous familial hypercholesterolemia
(heFH), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
9] It was approved by the US-FDA in July 2015 as a first-in-class drug, "for use in addition to diet and maximally tolerated statin therapy in adult patients with heterozygous familial hypercholesterolemia
(HeFH) or patients with clinical atherosclerotic cardiovascular disease such as heart attacks or strokes, who require additional lowering of LDL cholesterol.